Determination of Nateglinide in Tablet Formulation by HPLC Using a Pentafluorophenyl Core-Shell Column

Çağrı ÖZKURT1, Alper ÜNAL1, Orhan KILIÇ1, Deniz ÇIKLA YILMAZ2*

ABSTRACT: Nateglinide is an insulin secretagogue which has been used for the treatment of Type 2 Diabetes mellitus. A simple analytical methodology for determination of nateglinide in tablet formulation is described. An isocratic reversed phase high performance liquid chromatographic (HPLC) method was developed using Kinetex pentafluorophenyl (PFP) (5µm particle size and 4.6 x 150 mm id) core-shell column as stationary phase and 0.05 M Na2HPO4 (pH=2.0) / methanol (30:70 v/v) mixture as mobile phase with the flow rate of 1.0 mL min\(^{-1}\) and diode-array detector at 215 nm. Column was termostated at 22°C. Under these conditions nateglinide was eluted with a symmetrical peak shape and the retention time was 4.779 minutes. The system suitability parameters such as tailing factor, capacity factor and theoretical plate were evaluated. The method was validated as per International Council on Harmonisation (ICH) guidelines. Linearity was obtained in the 2.54 - 40.70 µg mL\(^{-1}\) concentration range with equation \(y= 10.818x + 4.7048\) (R\(^2\)= 0.998). Limit of detection and limit of quantification were 1.07 and 2.54 µg mL\(^{-1}\). Accuracy of the method was tested by recovery studies which were in the range of 98.78 - 100.76 %. The intra-day and inter-day precision studies were carried out and the relative standard deviation values of peak areas were within ICH limits. The proposed method was successfully applied to the determination of nateglinide in tablet dosage form.

Keywords: validation, HPLC, nateglinide, pentafluorophenyl, core-shell column

ÖZET: Nateglinid Tip 2 Diabetes mellitus tedavisinde kullanılan bir insülin salgılatıcıdır. Bu çalışmada tablet formülasyonundaki nateglinidin tayini için basit bir analitik yöntemi geliştirildi. İzokratik ters faz yüksek performanslı sıvı kromatografi (HPLC) yöntemi, sabit faz olarak Kinetex pentafluorofenil (PFP) (5µm partikül boyutu ve 4.6 x 150 mm kolon boyutu) core-shell kolon, hareketli faz olarak 0.05 M Na2HPO4 (pH=2.0) / metanol (30:70 v/v) karışımı 1.0 mL dk\(^{-1}\) akış ve 215 nm’de diod dizi dedektör kullanılarak geliştirildi. Termostat kontrollü kolon sıcaklığı 22°C’dir. Bu koşullar altında nateglinid 4.779 dakika alıkonma zamanı ve simetrik bir pik şekliyle elüe olmuştur. Kuyruklama faktörü, kapasite faktörü ve teorik plaka sayısı gibi sistem uygunluk parametreleri hesaplanmıştır. Analitik yöntemi validasyonunun gerektirdiği testler Uluslararası Uyum Konseyi (ICH) yönergelerine göre yapılmıştır. \(y= 10.818x + 4.7048\) (R\(^2\)= 0.998) doğrusal denklemi ile 2.54 – 40.70µg mL\(^{-1}\) konsantrasyon aralığında doğruşaluk bulundu. Teşhis sınırı 1.07 ve tayin sınırı 2.54 µg mL\(^{-1}\)dir. Yöntemin doğruluğu geri kazanım çalışması ile belirlendi ve yüzde geri kazanım 98.78 – 100.76 aralığında hesaplandı. Gün içi ve günler arası tekrarlanabilirlik çalışmalarıyla elde edilen pik alanlarının bağlı standard sapma değerleri ICH limitleri içerisinde bulunmuştur. Önerilen yöntem nateglinidin tablet formülasyonundan tayin edilmesinde başarıyla uygulanmıştır.

Anahtar Kelimeler: validasyon, HPLC, nateglinid, pentafluorofenil, core-shell kolon

1Çağrı ÖZKURT (Orcid ID: 0000-0001-9641-6745), Alper ÜNAL (Orcid ID: 0000-0003-2959-6226), Orhan KILIÇ (Orcid ID: 0000-0002-3343-6965), Faculty of Pharmacy, Marmara University, Istanbul, Turkey
2Deniz ÇIKLA YILMAZ (Orc ID: 0000-0001-6830-2011), Analytical Chemistry Department, Faculty of Pharmacy, Marmara University, Istanbul, Turkey

*Sorumlu Yazar/Corresponding Author: Deniz ÇIKLA YILMAZ, e-mail: deniz.yilmaz@marmara.edu.tr

*This study is produced from the graduation project of Çağrı Özkurt, Alper Ünal and Orhan Kılıç
INTRODUCTION

Nateglinide is an amino acid derivative with the chemical name $(-)$-N-(((trans-4-isopropropylcyclohexane carbonyl)-d-phenylalanine, it is a member of the drug class known as meglitinide antidiabetics. Meglitinides are short-acting antidiabetic agents which lower blood glucose levels by stimulating insulin secretion in pancreatic beta cells. Nateglinide is only taken about ten minutes before meals and was approved by the FDA in December 2000 for the treatment of type 2 diabetes mellitus (Maggi et al., 2013; Upadhyay et al., 2018). It appears as a white powder. It is insoluble in water; partially soluble in acetonitrile and octanol; soluble in chloroform, ether, methanol and ethanol (Frenkel et al., 2009).

Nateglinide has been determined alone in pharmaceutical formulations by spectrophotometry (Jain et al., 2009), HPLC (Hacıoğlu et al., 2015) and UPLC (Xavier et al., 2012). It has also been determined simultaneously with its degradation products and impurities (Madhavi et al., 2008), with metformin and meglinides class of antidiabetetics (El-Zaheer et al., 2018), fourteen synthetic antidiabetics (Cui et al., 2010) by UV detector and HPLC. Estimation of nateglinide in rabbit plasma (Sankalia et al., 2007), rat plasma (Dey et al., 2020) and urine (Lam et al., 2020) has been described. Among these studies, significant peak tailing of nateglinide on stationary phases was reported. To overcome this problem, Cui et al. reported the addition of sodium dodecyl sulfate and triethylamine in the mobile phase on a Diamonsil C18 column (Cui et al., 2010), El-Zaheer et al. presented the use of Lichorosper NH2 column and the tailing factor was given as 1.422 (El-Zaheer et al., 2018), Madhavi et al. used Zorbax C8 column and the tailing factor was given as 1.2 (Madhavi et al., 2008).

In recent years, new generation stationary phases containing core-shell particles have gained increasing attention in order to reduce analysis time and improve separation power. Different vendors commercialized stationary phases with a variety of chemistries, that is, C18, C8, HILIC (hydrophilic interaction liquid chromatography, phenylhexyl and pentafluorophenyl (Ali et al., 2012). Core-shell columns packed with pentafluorophenyl silica were applied with success for the analysis of tocopherols (Bakir et al., 2020), phenolic compounds (Serni et al., 2020) and fluoroquinolones (Yıldırım et al., 2020).

This study delineates the development and validation of an isocratic reversed phase HPLC method using a pentafluorophenyl core-shell column for the determination of nateglinide in pharmaceutical oral dosage form.

MATERIALS AND METHODS

Chemicals and Reagents

The chemicals used in this study were Nateglinide which was bought from Sigma-Aldrich, gradient grade methanol (LiChrosolv®), $H_3PO_4$ and extra pure NaH$_2$PO$_4$ which were bought from Merck. Teglix® film coated tablets, which were produced by Biofarma in Turkey and contained 120 mg of nateglinide according to its package information, were bought from a nearby pharmacy.

Instrument and Chromatographic Conditions

Agilent 1260 Infinity HPLC system was used in chromatographic analysis. The components of the HPLC system included Agilent 1260 Infinity Standard Autosampler (G1329B), Agilent 1260 Infinity Quaternary Pump (G1311B), Agilent 1260 Thermostatted Column Component (G1316A), Agilent 1260 Infinity Diode Array Detector (G1315D), and Kinetex PFP 100-5 (4.6 x 150 mm 5µm) column. The mobile phase used in this study was 0.1 M NaH$_2$PO$_4$ solution, with its pH adjusted to 2.0 using 0.1 M $H_3PO_4$. It was then diluted and mixed with methanol in a 30:70 (v/v) ratio. The detection wavelength was 215 nm and the separation was performed with the temperature kept at 22 °C. The flow rate was 1.0
ml min⁻¹ and the injection volume was 10 μL. Agilent ChemStation software was used in data evaluation. A hot air oven, an ultrasonic bath, a Mettler Toledo MP220 pH meter, and a Hettich Universal 32R centrifuge were also used in various stages of the study.

**Standard and Sample Solutions Preparations**

**Standard solution**

15.9 mg of nateglinide was weighed and dissolved in methanol in a 25 ml volumetric flask in order to prepare the standard nateglinide stock solution. The working standard solutions were prepared by dilution of the standard solution with the mobile phase and were used for the construction of the calibration curve.

**Tablet sample solution**

10 tablets were weighed and pulverized into powder with a mortar and pestle. The arithmetic average of the weights of ten tablets was calculated and the powder, assumed to contain 120 mg of nateglinide, was weighed. It was then put into a volumetric flask and dissolved with 100 ml of methanol. The solution was sonicated in an ultrasonic bath for 15 minutes before being centrifuged at 12000 rpm for 10 minutes. Then a solution containing 10.18 μg ml⁻¹ nateglinide was prepared by dilution with the mobile phase.

**RESULTS AND DISCUSSION**

At the start of the optimization of the chromatographic conditions, the pH of the buffer as the mobile phase component, was considered first. 0.05 M NaH₂PO₄ at pH 3.0 and pH 2.0 were tried. The tailing factor was calculated as 1.34402 at pH 3.0 and as 1.06151 at pH 2.0. As a result, the buffer pH was chosen as 2.0. The mobile phase ratio using methanol was determined by evaluating system suitability parameters *i.e.*, capacity factor, tailing factor and theoretical plate (CDER, 1998). A symmetrical peak was attained with the mixture of 0.05 M NaH₂PO₄ (pH 2.0)/methanol (70/30, v/v) at a flow rate of 1 mL min⁻¹. In Figure 1, the typical chromatogram obtained under these conditions is shown and system suitability parameters were given in Table 1. The retention time of nateglinide was 4.779 minutes which provided a sufficient analysis time. The detector was set at absorption maxima of nateglinide in methanol solution at a wavelength of 215 nm (Jain et al., 2009). The method was applied to commercial tablets and assay results were given at Table 2.

| Parameter          | Values  | Required limits |
|--------------------|---------|-----------------|
| Theoretical plate (N) | 9979    | N>2000          |
| Capacity factor (k')   | 2.31    | k'>2            |
| Tailing factor (T)     | 1.06151 | T<2             |

**Method Validation**

**Selectivity**

Injection of mobile phase showed no interference at the retention zone of nateglinide peak (Figure 1, 2 and 3). A representative chromatogram of tablet sample solution spiked with standard nateglinide solution demonstrated that no matrix components were found to interfere.
Determination of Nateglinide in Tablet Formulation by HPLC Using a Pentafluorophenyl Core Shell Column

Figure 1. Chromatogram of nateglinide standard solution.

Figure 2. Chromatogram of nateglinide tablet sample solution.

Figure 3. Chromatogram of mobile phase (blank).
Table 2. Assay results for the commercial tablets

| Labeled claim (mg) | Amount found (mg) | RSD% |
|--------------------|-------------------|------|
| 120                | 119.74            | 1.22 |

*n=3 (mean value)

Linearity and range

For the evaluation of linearity, replicates (n = 3) of five concentrations, which ranged from 2.54 to 40.70 μg mL⁻¹, were analyzed. Linear correlation was obtained between concentrations and the average peak areas. The equation of the linear regression line was \( y = 10.818x + 4.7048 \) with a correlation coefficient of \( R^2 = 0.998 \). The linearity curve of nateglinide is shown in Figure 4.

限界検出及び定量

The limit of detection and quantification was determined to be 1.07 μg mL⁻¹ and 2.54 μg mL⁻¹ with a single to noise ratio of 3:1 and 10:1 respectively.

Accuracy

Accuracy was determined by spiking standard nateglinide solution into the analyzed tablet sample solution at three different levels (80, 100 and 120). As can be seen from Table 3, the percentage of recoveries were in the range of 98.68 - 100.76 and relative standard deviation (RSD%) values <2 confirms the accuracy of the method (ICH, 2005).

Table 3. Results of the accuracy study.

| Accuracy level | Amount of drug taken (mg) | Amount of drug spiked (mg) | Recovery* % | RSD % |
|----------------|---------------------------|---------------------------|-------------|-------|
| 80             | 120                       | 96                        | 100.76      | 0.68  |
| 100            | 120                       | 120                       | 99.21       | 0.52  |
| 120            | 120                       | 144                       | 98.68       | 1.18  |

*n=3 (mean value)
Precision

The precision of the method was evaluated through interday and intraday repeatability experiments. To assess the intraday repeatability, six consecutive injections of 20.35 µg ml⁻¹ nateglinide solution were performed in one day. RSD value of nateglinide peak areas was found to be 0.38. To assess the interday repeatability, injections of the aforementioned solution were performed in three separate days. RSD value of nateglinide peak areas was found to be 0.84 %, which is within the acceptance criterion (ICH, 2005).

Robustness

By intentionally changing the conditions including temperature and flow rate, the robustness test was evaluated. Our data at Table 4 shows that, while the results remained unaffected by changes in the temperature, there were small variations arising from changes in the flow rate.

Table 4. Results of the robustness study

| Parameter      | TR*  | Calculated Conc. % * |
|----------------|------|----------------------|
| Flow rate      |      |                      |
| (1mL min⁻¹)    |      |                      |
| 0.95           | 5.068| 104.39               |
| 1.00           | 4.851| 100.00               |
| 1.05           | 4.565| 95.31                |
| T              |      |                      |
| (22°C)         |      |                      |
| 21             | 4.853| 99.09                |
| 22             | 4.851| 100.00               |
| 23             | 4.800| 99.18                |

TR*: Retention time, *n= 3 (mean value)

CONCLUSION

This study is a typical example of the development of a quantification method for drug substance in tablet formulation and the establishment of the validation of the analytical procedure by ICH instructions. The method described here using new generation core-shell column with a pentafluorophenyl stationary phase provided a symmetrical nategline peak. The fluorinated phases can provide solutions for the peak tailing problem on conventional C18 bonded silica columns in reversed phase liquid chromatography.

Based on the above results, the developed method is simple with a short analysis time and validation studies proved the reliability of the method which can be useful for quality control in industrial laboratories. However further investigations can be performed concerning to the related impurities and degradation products of nateglinide.

REFERENCES

Ali I, Al-OthmanZA, Nagae N, GaitondeVD, DuttaKK, 2012. Recent trends in ultra-fast HPLC: New generation superficially porous silica columns. Journal of Separation Science, 35: 3235–3249.

BakirDS, YalçınG, CucuAK, 2020. Isolation and Determination of Tocopherols and Tocotrienols from the Seed of Capparis Ovata Grown in Turkey by Reversed-Phase High-Performance Liquid Chromatography. Chromatographia, 83: 77–86.

CDER, 1998. Reviewer Guidance - Validation of chromatographic methods. Center for Drug Evaluation and Research.

Cui M, Li N, Qin F, Li F, Xiong Z, 2010. Simultaneous determination of 14 illegal adulterants in Chinese proprietary medicines using reversed-phase ion-pair LC. Chromatographia, 72: 1189–1194.

Dey S, Basak S, De A, Alam SP, Hossain T, Saha A, Ghosh M, Karmakar T, 2020. Simultaneous Pharmacokinetics Estimation of Nateglinide and Pioglitazone by RP-HPLC: Computational Study to Unlock the Synergism. Journal of Chromatographic Science, 58: 309–322.
El-Zaher AA, Elkady EF, Elwy HM, Saleh MAEM, 2018. A new rapid and economic liquid chromatographic method for simultaneous determination of meglitinides with metformin: application in the presence of metformin and repaglinide impurities and related compounds. Journal of the Iranian Chemical Society, 15: 61–74.

Frenkel G, Sheva B, Gome B, Lezio R, Wizel S, Tiqva P, 2009. United States Patent. US 7,534,913 B2.

Hacıoğlu A, Çıtlak A, Karakuş S, 2015. Nateglinid etken maddesinin miktar tayini için HPLC yönteminin geliştirilmesi ve validasyonu. Marmara Pharmaceutical Journal, 19: 103–108.

ICH, 2005. Validation of Analytical Procedure: Text and Methodology Q2 (R1). ICH Steering Comittee.

Jain S, Bhandari A, Purohit S, 2009. Spectrophotometric determination of nateglinide in bulk and tablet dosage forms. Asian Journal of Pharmaceutics, 3: 218–221.

Lam YH, Leung MT, Ching CK, Mak TWL, 2020. Simultaneous detection of 24 oral antidiabetic drugs and their metabolites in urine by liquid chromatography–tandem mass spectrometry. Journal of Chromatography B, 1141.

Madhavi A, Reddy GS, Suryanarayana M V., Naidu A, 2008. Development of a new analytical method for determination of related components in nateglinide. Chromatographia, 67: 639–645.

Maggi L, Bruni G, Maietta M, Canobbio A, Cardini A, Conte U, 2013. I. Technological approaches to improve the dissolution behavior of nateglinide, a lipophilic insoluble drug: Nanoparticles and co-mixing. International Journal of Pharmaceutics, 454: 562–567.

Sankalia JM, Sankalia MG, Sutariya VB, Mashru RC, 2007. Nateglinide quantification in rabbit plasma by HPLC: Optimization and application to pharmacokinetic study. Journal of Pharmaceutical and Biomedical Analysis, 44: 196–204.

Serni E, Venier E, Romano G, Guerra W, Robatscher P, 2020. Determination of Major Phenolics Content in Dried Apples from Three New Cultivars (Malus domestica Borkh.) Using HPLC-UV-FL with Pentafluorophenyl Stationary Phase. Food Analytical Methods, 13: 863–871.

Upadhyay J, Polyzos SA, Perakakis N, Thakkar B, Paschou SA, Katsiki N, Underwood P, Park KH, Seufert J, Kang ES, Sternthal E, Karagiannis A, Mantzoros CS, 2018. Pharmacotherapy of type 2 diabetes: An update. Metabolism: Clinical and Experimental, 78: 13–42.

Xavier CM, Basavaiah K, Ramesh J, Vinay KB, Revanasiddappa HD, 2012. RP-UPLC Method Development and Validation for the Determination of Nateglinide in Bulk Drug and Pharmaceutical Formulations : A Quality by Design Approach. Malaysian Journal of Pharmaceutical Sciences, 10: 23–44.

Yıldırım S, Karakoç HN, Yaşar A, Köksal İ, 2020. Determination of levofloxacin, ciprofloxacin, moxifloxacin and gemifloxacin in urine and plasma by HPLC-FLD-DAD using pentafluorophenyl core-shell column: Application to drug monitoring. Biomedical chromatography : BMC: e4925.